Market Overview

Global Hunter Reiterates Buy on Auxilium Pharmaceuticals (AUXL)


Global Hunter is out with its report today on Auxilium Pharmaceuticals (NASDAQ: AUXL), reiterating Buy.

In a note to clients, Global Hunter writes, "Upcoming events for Auxilium include Q1 earnings and a three-year safety update in patients with Dupuytren's contracture expected in June. In addition, we anticipate clarity regarding the regulatory pathway in Japan this year and additions of other ROW partnerships. In our view, there remains significant upside to our fair value giving our long-term growth prospects and attractive valuation. We continue to anticipate shares to appreciate during the XIAFLEX launch with the potential realization of catalysts providing upside to our estimates. Thus, we reiterate our Buy rating and $27 price target."

At the time of posting, shares of AUXL were trading at $21.99, down 0.09% from Tuesday's close.

Posted-In: Auxilium Pharmaceuticals Global HunterAnalyst Color Price Target Analyst Ratings


Related Articles (AUXL)

View Comments and Join the Discussion!

Latest Ratings

POWLSidoti & Co.Maintains47.0
XDeutsche BankInitiates Coverage On121.0
WTEBMO CapitalMaintains18.0
DOLBMO CapitalMaintains50.0
NABMO CapitalMaintains69.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

I've Got a Funny Feeling About the Stock Market

AIG Says Japanese Earthquake Exposure Is $508M Maximum -CNBC (AIG)